What the FDA labels say about taking them together
Ceritinib and midazolam
Ceritinib's FDA label of December 15, 2025 names midazolam in its drug interactions section; the midazolam labels PlainMeds reads (4) do not name ceritinib. The ceritinib label: “Ceritinib increased the systemic exposure of a sensitive CYP3A substrate (midazolam).”
Check it at the source: the ceritinib FDA label on DailyMed (effective December 15, 2025, Novartis Pharmaceuticals Corporation); the midazolam FDA label on DailyMed (effective January 1, 2024, Fresenius Kabi USA, LLC).
What does the ceritinib label say about midazolam?
Ceritinib label, drug interactionsCeritinib increased the systemic exposure of a sensitive CYP3A substrate (midazolam) [see Clinical Pharmacology (12.3)].
Source: FDA drug label (ZYKADIA), Novartis Pharmaceuticals Corporation, effective December 15, 2025 (SPL set fff5d805-4ffd-4e8e-8e63-6f129697563e), via openFDA; the full label on DailyMed
What does the midazolam label say about ceritinib?
Midazolam's label (effective January 1, 2024) and its 3 other brand-application labels do not name ceritinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Midazolam), Fresenius Kabi USA, LLC, effective January 1, 2024 (SPL set 1cc9ba6e-fa1b-405e-9de8-720c567b2a73), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ceritinib | Midazolam | |
|---|---|---|
| Labeled for | Lung cancer | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.233 per mL 2 mg/2 mL vial |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once